Tradestie Institutional Equity Comparison Engine
BCAX vs MBX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
MBX Overall Edge
MBX Captures Institutional Edge (3โ0 Pillars ยท 4โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to MBX Biosciences, Inc. Common Stock (MBX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, BCAX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MBX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, BCAX sits in BREAKDOWN (23rd %ile IV; Dealer Gamma Walls on Pro) against MBX sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
BCAX N/M vs MBX N/M Fwd P/E
Growth & Margin Winner
MBX
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner
MBX
1Y -32.8% vs +122.4% ยท 52W Pos 7% vs 62%
Options & Structure Winner
MBX
BREAKDOWN (23rd %ile IV) vs UNCLASSIFIED (<1st %ile IV)
BCAX
NASDAQ
Bicara Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$9.58
-4.39% 1D
Market Cap
$671.2M
1M Return
-42.91%
1Y Return
-32.82%
Forward P/E
N/M
Unified AI Score
52.1 / 100
HOLD
Tech 58.0
Fund 66.0
Flow 68.0
Mom 64.0
MBX
NASDAQ
MBX Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$53.54
-4.29% 1D
Market Cap
$2.7B
1M Return
+7.92%
1Y Return
+122.43%
Forward P/E
N/M
Unified AI Score
44.9 / 100
HOLD
Tech 42.0
Fund 47.0
Flow 50.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
BCAX -32.82%
MBX +122.43%
Spread: +155.25 pp (MBX Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
BCAX TTM Op. Margin: 0.0%
MBX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BCAX vs MBX. Trailing 12-month operating profitability (BCAX 0.0% vs MBX 0.0%) and valuation multiples (BCAX N/M vs MBX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BCAX | MBX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $671.2M | $2.7B | Larger Scale | MBX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -54.2% | -33.7% | Higher ROE | MBX |
| 52-Week Range Position Momentum | 7% ($8โ$31) | 62% ($23โ$73) | Stronger Trend | MBX |
| Beta / 30D Volatility Risk Regime | 1.41ฮฒ ยท 184% Vol | 1.58ฮฒ ยท 66% Vol | Lower Realized Risk | MBX |
| Unified Institutional Score Composite Signal | 52.1 / 100 (HOLD) | 44.9 / 100 (HOLD) | Higher Composite | BCAX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full BCAX vs MBX Buy Guide
BCAX
BREAKDOWN
93d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
23rd %ile
IV Regime
Compressed (<25th %ile)
MBX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither BCAX nor MBX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.